Skip to content

Study · Animal study (in vivo) · 1987

5 results

Influence of protease inhibitors on the antidepressant activity of oxytocin.

Arletti R, Bertolini A

Neuropeptides1 Oct 1987Cited by 11 (Europe PMC)

PMID2891075 (opens in a new tab)DOI10.1016/0143-4179(87)90074-6 (opens in a new tab)PepBankPUB-02891075
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In the behavioral despair test, MIF‑1 was inactive.

    In plain wordsIn animal tests, MIF‑1 was inactive in the behavioral despair test.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeBehavioral despair test activity
    Study

    n: not reported in source

    Behavioral despair test
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    On the other hand, the linear tripeptide tail of oxytocin, MIF-1, was inactive in the behavioral despair test, and less active than oxytocin in the learned helplessness test.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In the learned helplessness test, MIF‑1 was less active than oxytocin.

    In plain wordsIn animal tests, MIF‑1 was less active than oxytocin in the learned helplessness test.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseLearned helplessness test activity
    Study

    n: not reported in source

    Learned helplessness test
    Comparator
    Oxytocin
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    On the other hand, the linear tripeptide tail of oxytocin, MIF-1, was inactive in the behavioral despair test, and less active than oxytocin in the learned helplessness test.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In the learned helplessness test, oxytocin was more active than MIF-1.

    In plain wordsIn animal tests, oxytocin was more active than MIF-1 in the learned helplessness test.

    Peptide
    Oxytocin
    Outcome
    IncreaseLearned helplessness test activity versus MIF-1
    Study

    n: not reported in source

    Learned helplessness test
    Comparator
    MIF-1
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    0.500 mg/Kg · i.p.As given in this study.

    Source sentences

    Summary
    On the other hand, the linear tripeptide tail of oxytocin, MIF-1, was inactive in the behavioral despair test, and less active than oxytocin in the learned helplessness test.
    1 context sentence
    Summary · context
    Both in the behavioral despair test and in the learned helplessness test, the antidepressant-like activity of oxytocin (0.500 mg/Kg i.p.) was prevented by the administration of a protease inhibitor (EACA, 400 mg/Kg i.p.; pepstatin, 0.1 mg/Kg i.p.).

Studies that did not test the peptide alone2

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 04AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Efficacy outcome

    In the behavioral despair test, protease inhibitors prevented oxytocin's antidepressant-like activity.

    In plain wordsIn animal tests, protease inhibitors blocked oxytocin's antidepressant-like activity in the behavioral despair test.

    Peptide
    Oxytocin
    Outcome
    DecreaseAntidepressant-like activity in behavioral despair test
    Study

    n: not reported in source

    Behavioral despair test
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    Both in the behavioral despair test and in the learned helplessness test, the antidepressant-like activity of oxytocin (0.500 mg/Kg i.p.) was prevented by the administration of a protease inhibitor (EACA, 400 mg/Kg i.p.; pepstatin, 0.1 mg/Kg i.p.).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  2. 05AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Efficacy outcome

    In the learned helplessness test, protease inhibitors prevented oxytocin's antidepressant-like activity.

    In plain wordsIn animal tests, protease inhibitors blocked oxytocin's antidepressant-like activity in the learned helplessness test.

    Peptide
    Oxytocin
    Outcome
    DecreaseAntidepressant-like activity in learned helplessness test
    Study

    n: not reported in source

    Learned helplessness test
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    Both in the behavioral despair test and in the learned helplessness test, the antidepressant-like activity of oxytocin (0.500 mg/Kg i.p.) was prevented by the administration of a protease inhibitor (EACA, 400 mg/Kg i.p.; pepstatin, 0.1 mg/Kg i.p.).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:52 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.